Review Article

HSS Journal

, Volume 5, Issue 2, pp 159-160

First online:

Is There a Role for NFAT Inhibitors in the Prevention of Bone Destruction?

  • Mark S. McMahonAffiliated withDepartment of Orthopedic Surgery, Beth Israel Deaconess Medical CenterDepartment of Developmental Biology, Harvard SDM Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Pathologic conditions resulting from excessive bone destruction include osteoporosis, rheumatoid arthritis, metastases, periprosthetic osteolysis, cherubism, and others. A scarcity of molecular targets in bone has thwarted the development of drugs to combat these conditions. Nuclear factor of activated T-cells (NFAT) is a master regulator of osteoclastogenesis and is induced by RANKL. The immunosuppressive drugs, Cyclosporin A and Tacrolimus, inhibit osteoclast formation by targeting the NFAT/calcineurin pathway. These NFAT inhibitors should be considered in the treatment of osteoclastic hyper-resorptive syndromes.


osteoclast NFAT Cyclosporin A Tacrolimus calcineurin